For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of Vyndamax and Attruby represents a significant breakthrough . These innovative therapies preserve the transthyretin protein, slowing its harmful build-up and alleviating the severity o